Prakash Raman
Directeur/Bestuurslid bij BLACK DIAMOND THERAPEUTICS, INC.
Vermogen: 10 999 $ op 31-05-2024
Profiel
Prakash Raman is currently the Chief Executive Officer at Indupro and an Independent Director at Black Diamond Therapeutics, Inc. He is also a Director at NAYA Biosciences, Inc. Previously, he served as the Co-Chief Executive Officer & Director at KSQ Therapeutics, Inc. and as the President, Chief Executive Officer & Director at Ribon Therapeutics, Inc. Dr. Raman was also the VP & Global Head-NIBR Business Development at Novartis Institutes for Biomedical Research, Inc. He started his career as the Head-Project Management at AstraZeneca PLC.
Dr. Raman holds a doctorate degree from the University of Wisconsin and an undergraduate degree from the Indian Institute of Technology Bombay.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-06-2024 | 2 301 ( 0.00% ) | 10 999 $ | 31-05-2024 |
Actieve functies van Prakash Raman
| Bedrijven | Functie | Begin |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Directeur/Bestuurslid | 10-04-2024 |
| Indupro | Algemeen Directeur | 13-06-2024 |
Eerdere bekende functies van Prakash Raman
| Bedrijven | Functie | Einde |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | 01-11-2012 |
KSQ Therapeutics, Inc.
 KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Algemeen Directeur | - |
Ribon Therapeutics, Inc.
 Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Algemeen Directeur | - |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Opleiding van Prakash Raman
| University of Wisconsin | Doctorate Degree |
| Indian Institute of Technology Bombay | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Health Technology |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Health Technology |
| Indupro |
